Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05113862
Other study ID # naNO-COVID
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 10, 2022
Est. completion date September 15, 2022

Study information

Verified date November 2022
Source Emergex Vaccines Holding Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is Stage 2 of a 2-part adaptive trial. The study aims to investigate the safety of 2 doses of a T-cell priming specific cocktail of Coronaviruses peptides mounted on a gold nanoparticle. Note: Stage 1 of the 2-part adaptive trial, testing a specifically selected mix of Dengue virus peptides, commenced Aug 2021. This is now in follow up (NCT04935801).


Description:

Despite drastic quarantine measures, SARS-CoV-2 continues to propagate and threaten global economies and healthcare systems. There is universal consensus on the need for vaccination to protect against complications, reduce viral shedding and therefore prevent severe manifestation of disease and reduce hospitalisations. Coronavirus harbours the potential to become a seasonal disease. It is moving towards being a ''new flu'' with potential perennial circulation and continuously evolving Variants of Concern (VOCs), needing diverse vaccines to control it. The Global Vaccine Alliance, GAVI, has specifically advocated for vaccine diversity as a means to ensure equality and access as well as a means of maximising scalability. Nanoparticle antigen delivery systems have been developed to enrich specific targeting of immune receptors. These carrier systems are designed to facilitate antigen uptake and processing by antigen presenting cells (APCs), as well as to control antigen release and protect them from premature proteolytic degradation. This more targeted response also allows to reduce the effective antigen dose (to nanomoles) and mimic a replicating infection with zero risk of developing the infectious disease. The hypotheses are listed below: 1. The scale of the COVID-19 pandemic requires multiple vaccine candidates to ensure democratic and rapid access to protection by: - Providing a range of vaccine choices tailored to variations in immunological profiles across demographics as well as suited to environments with various levels of resources (cold chain etc). - Distributing and parallelizing manufacture, to speed up scale, avoid reagent stock limitations and dilute monopolies. 2. The ability for SARS-CoV-2 to mutate, requires multiple vaccine candidates to ensure robust and sustainable protection. Vaccines with a range of epitopes and immune targets provide immunological diversity and reduce vulnerability to mutant escape. 3. Nanotechnology fulfils the needs of a COVID vaccine by being a rapidly scalable and modular platform. 4. Humoral immunity may be transient and insufficient against emerging variants of SARS-CoV-2. 5. Cellular immunity against SARS-CoV-2 is lasting and associated with recovery in COVID-19. The proposed vaccine of this trial specifically seeks to diversify the immunological target response by carefully curating an MHC-I binding antigen cocktail from the SARS viruses ligandome and loading it onto a robust nanoparticle for controlled release and coupled T-cell immunostimulation. It also specifically seeks to avoid generating a humoral response, which has the potential to be transient and even detrimental in certain cases. For this second stage of the trial, the objectives are are follows: Primary: To evaluate the safety and reactogenicity of two intradermal injections of two different doses of the investigational COVID peptide T-cell inducing vaccine (PepGNP-Covid19) administered to healthy volunteers in Switzerland as a: 1. candidate vaccine for the prevention of COVID-19 2. proof-of-concept for a rapidly scalable modular peptide vaccine platform. Secondary: 1. To assess the evidence of a CD8 T-cell mediated immune response as a surrogate of protection against severe COVID-19 disease using a novel peptide set-point vaccine in healthy adults. 2. To assess the presence of an antibody mediated response. For naNO-COVID, a total of 26 eligible participants will be randomised into the following groups: Group 1 (n=13) 10 low dose (LD) PepGNP-Covid19 (2.5nmol peptide +12.8ug) + 3 Comparator. Group 2 (n=13) 10 high dose (HD) PepGNP-Covid19 (7.5nmol + 38.3ug) + 3 Comparator. Thus, 20/26 vaccine and 6/26 Comparator controls. Allocations of vaccine vs bpC for each group are double-blinded. Each arm will be staggered into a ''Pioneer'' group (3/13 participants) followed a week later after a safety review by the remaining 10/13 ''Followers''. This is the second stage of a 2-stage study investigating the safety of 2 vaccines from a T-cell priming vaccine platform for emerging diseases. (stage 1 = naNO-Dengue, stage 2 = naNO-COVID).


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date September 15, 2022
Est. primary completion date September 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Aged 18 to 45 years on the day of inclusion - Participant signed informed consent - Residing in Switzerland Exclusion Criteria: - Participant is pregnant, lactating or of childbearing potential - Participation in the 4 weeks preceding the first trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device or medical procedure. - Receipt of any vaccine (including vaccine against COVID) in the 4 weeks preceding the first trial vaccination (excluding influenza vaccination which may be received 2 weeks prior to the first vaccination), or planned receipt of any vaccine in the 4 weeks following each trial vaccination. - Positive SARS-CoV2 test in the 4 weeks preceding the first trial vaccination. - Receipt of immunoglobins, blood or blood-derived products in the past 3 months. - Known, or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy. - Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B natural infection, (HBcAb positive serology) or hepatitis C. - Known systemic hypersensitivity to any of the vaccine components (e.g gold,) or history of a life-threatening reaction to vaccines. - Current alcohol abuse or drug addiction (reported or suspected) - Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion. - Thrombocytopenia or any coagulation disorder - Identified as an Investigator or employee of the Investigator or study centre with direct involvement in the proposed study, or identified as an immediate family member (i.e parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study (i.e in the employment of the Tropivac Clinic or DFRI unit at Unisante). - Refusal to be informed in the event that relevant results concerning the participant's health are revealed. The following events constitute contraindications to the administration of the investigational product on the day of planned vaccination: The participant must be followed until resolution of the event as with any medical event and may be considered for vaccination at a later date (maximum 14 days later) or withdrawn at the discretion of the Investigator. Delays due to these events do not constitute a protocol deviation. - Temperature of >37.5°C at the time of vaccination - Acute disease at the time of vaccination (defined as the presence of a moderate or severe illness with or without fever according to investigator's judgment. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature of = 37.5°C).

Study Design


Intervention

Biological:
LD Vehicle-GNP
Two intradermal injections in the upper arm spaced 21 days apart
LD PepGNP-Covid19
Two intradermal injections in the upper arm spaced 21 days apart
HD Vehicle-GNP
Two intradermal injections in the upper arm spaced 21 days apart
HD PepGNP-Covid19
Two intradermal injections in the upper arm spaced 21 days apart

Locations

Country Name City State
Switzerland Center for Primary Care and Public Health (Unisante) Lausanne Vaud

Sponsors (3)

Lead Sponsor Collaborator
Emergex Vaccines Holding Ltd. Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland, University of Lausanne Hospitals

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety: Solicited local & systemic AEs Number of volunteers overall and in each dose group with local or systemic vaccine reactogenicity, based on evaluation of solicited adverse events (AEs) recorded on subject memory aids or during clinical assessments Through 14 days after prime or boost vaccination
Primary Safety: Unsolicited AEs Number of volunteers overall and in each dose group with unsolicited vaccine-associated adverse events (AEs) in each dose group Study Days 0-180 or through termination visit, if terminated early
Primary Safety: SAEs Number of volunteers overall and in each dose group with vaccine-associated serious adverse events (SAEs) Study Days 0-180 or through termination visit, if terminated early
Primary Safety: Adverse Events of Special Interest (AESI) Number of volunteers overall and in each dose group with vaccine-associated adverse events of special interest (AESIs) Study Days 0-180 or through termination visit, if terminated early
Secondary Immunogenicity: Proportion of participants with CD8-T cell specific to PepGNP-Covid19 Frequency of CD8+ T cells specific for individual CTL peptides by flow cytometry, using ex vivo MHC I dextramer staining and activation-induced markers (AIM) Study Days 0-180 or through termination visit, if terminated early
Secondary Proportion of participants becoming seropositive (antibodies against SARS-CoV-2) Geometric mean titre and geometric mean fold rise of antibodies against SARS-CoV2 as determined by Enzyme-linked Immunosorbent Assay (ELISA) Study Days 0-180 or through termination visit, if terminated early
See also
  Status Clinical Trial Phase
Recruiting NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Active, not recruiting NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Spikogen Booster Study Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure